Ikai Iwao, Itai Yuji, Okita Kiwamu, Omata Masao, Kojiro Masamichi, Kobayashi Kenichi, Nakanuma Yasuni, Futagawa Shunji, Makuuchi Masatoshi, Yamaoka Yoshio
The Liver Cancer Study Group of Japan, 403 Bear House, 40 Sanno-cho, Shogoin, Sakyo-ku, Kyoto, Japan
Hepatol Res. 2004 Jan;28(1):21-29. doi: 10.1016/j.hepres.2003.08.002.
In the 15th Nationwide follow-up survey of primary liver cancer, 18,843 newly registered patients (1998-1999) and 18,405 follow-up patients from 791 hospitals in Japan were analyzed. Of the newly registered patients, approximately 95% were patients with hepatocellular carcinoma (HCC) and 3.3% had intrahepatic cholangiocarcinoma (ICC). The patients were assessed using 194 items that were related to epidemiological and clinicopathological factors, diagnosis, and treatment. Furthermore, the survival rates of all of the newly registered patients in the 10th-15th follow-up survey were calculated for each histological type, background factor(s) and treatment, respectively. In patients with hepatocellular carcinoma, the survival rates of patients who underwent hepatectomy, ethanol injection therapy, microwave coagulation therapy, or transcatheter arterial embolization were calculated by tumor size, tumor number, and clinical stage. This follow-up survey will be helpful to assess the progress of research and medical practice in the treatment of primary liver cancer.
在第15次全国原发性肝癌随访调查中，对日本791家医院的18843例新登记患者（1998 - 1999年）和18405例随访患者进行了分析。在新登记患者中，约95%为肝细胞癌（HCC）患者，3.3%为肝内胆管癌（ICC）患者。使用194项与流行病学和临床病理因素、诊断及治疗相关的项目对患者进行评估。此外，分别针对每种组织学类型、背景因素和治疗方法，计算了第10 - 15次随访调查中所有新登记患者的生存率。在肝细胞癌患者中，根据肿瘤大小、肿瘤数量和临床分期，计算接受肝切除术、乙醇注射疗法、微波凝固疗法或经导管动脉栓塞术患者的生存率。这项随访调查将有助于评估原发性肝癌治疗的研究进展和医疗实践情况。
